JPH02164827A - Remedy for steatorrhea - Google Patents
Remedy for steatorrheaInfo
- Publication number
- JPH02164827A JPH02164827A JP31645488A JP31645488A JPH02164827A JP H02164827 A JPH02164827 A JP H02164827A JP 31645488 A JP31645488 A JP 31645488A JP 31645488 A JP31645488 A JP 31645488A JP H02164827 A JPH02164827 A JP H02164827A
- Authority
- JP
- Japan
- Prior art keywords
- 1alpha
- dihydroxyvitamin
- steatorrhea
- active type
- hydroxyvitamin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010041969 Steatorrhoea Diseases 0.000 title claims abstract description 11
- 208000001162 steatorrhea Diseases 0.000 title claims abstract description 11
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims abstract description 12
- 229930003316 Vitamin D Natural products 0.000 claims abstract description 11
- 235000019166 vitamin D Nutrition 0.000 claims abstract description 11
- 239000011710 vitamin D Substances 0.000 claims abstract description 11
- 150000003710 vitamin D derivatives Chemical class 0.000 claims abstract description 11
- 229940046008 vitamin d Drugs 0.000 claims abstract description 11
- 239000004480 active ingredient Substances 0.000 claims abstract description 6
- OFHCOWSQAMBJIW-AVJTYSNKSA-N alfacalcidol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C OFHCOWSQAMBJIW-AVJTYSNKSA-N 0.000 claims abstract description 5
- GMRQFYUYWCNGIN-NKMMMXOESA-N calcitriol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C GMRQFYUYWCNGIN-NKMMMXOESA-N 0.000 claims abstract description 3
- FCKJYANJHNLEEP-OIMXRAFZSA-N 24,25-Dihydroxyvitamin D Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCC(O)C(C)(C)O)C)=C\C=C1\C[C@H](O)CCC1=C FCKJYANJHNLEEP-OIMXRAFZSA-N 0.000 claims abstract 2
- 239000003814 drug Substances 0.000 claims description 6
- 229940124597 therapeutic agent Drugs 0.000 claims description 5
- 208000004155 Malabsorption Syndromes Diseases 0.000 abstract description 7
- 210000003608 fece Anatomy 0.000 abstract description 3
- 230000000694 effects Effects 0.000 abstract description 2
- -1 1alpha Chemical compound 0.000 abstract 1
- 230000001747 exhibiting effect Effects 0.000 abstract 1
- 239000003925 fat Substances 0.000 abstract 1
- 239000004615 ingredient Substances 0.000 abstract 1
- 229930003231 vitamin Natural products 0.000 abstract 1
- 229940088594 vitamin Drugs 0.000 abstract 1
- 235000013343 vitamin Nutrition 0.000 abstract 1
- 239000011782 vitamin Substances 0.000 abstract 1
- 206010025476 Malabsorption Diseases 0.000 description 5
- 238000002271 resection Methods 0.000 description 5
- 238000001356 surgical procedure Methods 0.000 description 4
- 230000005856 abnormality Effects 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 102000038379 digestive enzymes Human genes 0.000 description 3
- 108091007734 digestive enzymes Proteins 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 239000003793 antidiarrheal agent Substances 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000000378 dietary effect Effects 0.000 description 2
- 229940079919 digestives enzyme preparation Drugs 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 201000006549 dyspepsia Diseases 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 210000000813 small intestine Anatomy 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- JWUBBDSIWDLEOM-XHQRYOPUSA-N (3e)-3-[(2e)-2-[1-(6-hydroxy-6-methylheptan-2-yl)-7a-methyl-2,3,3a,5,6,7-hexahydro-1h-inden-4-ylidene]ethylidene]-4-methylidenecyclohexan-1-ol Chemical compound C1CCC2(C)C(C(CCCC(C)(C)O)C)CCC2\C1=C\C=C1/CC(O)CCC1=C JWUBBDSIWDLEOM-XHQRYOPUSA-N 0.000 description 1
- GMRQFYUYWCNGIN-UHFFFAOYSA-N 1,25-Dihydroxy-vitamin D3' Natural products C1CCC2(C)C(C(CCCC(C)(C)O)C)CCC2C1=CC=C1CC(O)CC(O)C1=C GMRQFYUYWCNGIN-UHFFFAOYSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 235000021318 Calcifediol Nutrition 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 229940125714 antidiarrheal agent Drugs 0.000 description 1
- 235000020964 calcitriol Nutrition 0.000 description 1
- 239000011612 calcitriol Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000013110 gastrectomy Methods 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 210000003405 ileum Anatomy 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 229920002113 octoxynol Polymers 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000079 pharmacotherapeutic effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 235000005282 vitamin D3 Nutrition 0.000 description 1
- 239000011647 vitamin D3 Substances 0.000 description 1
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 1
- 229940021056 vitamin d3 Drugs 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
【発明の詳細な説明】 本発明は、脂肪便の治療剤に関するものである。[Detailed description of the invention] The present invention relates to a therapeutic agent for steatorrhea.
脂肪便は脂肪の消化吸収不良によって生じ、吸収不良症
候群でしばしばよく認められる症状である。Steatorrhea is caused by maldigestion and absorption of fat and is often a common symptom of malabsorption syndromes.
この吸収不良症候群とは、消化・吸収の異常を臨床的に
一括総称したものであり、小腸にお（プる消化・吸収過
程の異常に基づく本態性吸収不良症候群；クローン病、
小腸広範囲切除術後などにみられる症候性吸収不良症候
群；および胃切除後のように吸収異常よりもむしろ消化
異常が主役を演じる消化障害性吸収不良症の３種類に大
別される。Malabsorption syndrome is a clinical collective term for abnormalities in digestion and absorption, and includes essential malabsorption syndrome, Crohn's disease,
It is broadly divided into three types: symptomatic malabsorption syndrome, which occurs after wide small intestine resection; and dyspepsia malabsorption syndrome, in which digestive abnormality plays a leading role rather than absorption abnormality, as occurs after gastrectomy.
現在、脂肪便の治療は、原疾患の治療と対症的薬物治療
に分けて行なわれている。対症的薬物療法としては食事
療法、消化酵素製剤、止瀉薬などが用いられている。し
かしながら、前述したように原疾患が多岐にわたるため
、食事療法の場合には患者の負担が大きいこと、消化酵
素製剤の場合には消化酵素の選択が非常に煩雑で面倒な
こと、さらには止瀉剤の場合には副作用を伴うことなど
、問題点も多い。Currently, treatment for steatorrhea is divided into treatment of the underlying disease and symptomatic drug treatment. Dietary therapy, digestive enzyme preparations, antidiarrheal drugs, etc. are used as symptomatic drug therapy. However, as mentioned above, the underlying diseases are diverse, so dietary therapy places a heavy burden on the patient, digestive enzyme preparations require the selection of digestive enzymes to be extremely complicated and troublesome, and antidiarrheal agents There are many problems, including side effects.
我々は従来より活性型ビタミンＤについての研究を行っ
てきたが、今回、活性型ビタミンＤが脂肪便に対して著
明な治療効果を示すことを知見じ本発明に到達した。We have been conducting research on active vitamin D, and now we have arrived at the present invention after discovering that active vitamin D has a significant therapeutic effect on steatorrhea.
即ち、本発明は活性型ビタミンＤを有効成分とする脂肪
便治療剤である。That is, the present invention is a therapeutic agent for steatorrhea containing active vitamin D as an active ingredient.
本発明における活性型ビタミンＤには活性型ビタミンＤ
２ 、活性型ビタミンＤ３ 、及びそれらの誘導体が含
まれる。かかる活性型ビタミンＤの具体例としては、例
えば１α−ヒドロキシビタミンＤ、１α、２４−ジヒド
ロキシビタミンＤ、１α。Active vitamin D in the present invention includes active vitamin D.
2, active vitamin D3, and their derivatives. Specific examples of such active vitamin D include 1α-hydroxyvitamin D, 1α,24-dihydroxyvitamin D, and 1α.
２５−ジヒドロキシビタミンＤ、 ２４．２５−ジヒド
ロキシビタミンＤ、 ２４．２４−Ｆ２−１α、２５−
ジヒドロキシビタミンＤ、 ２６，２６，２６，２７，
２７．２７−Ｆｅ−１α、２５−ジヒドロキシビタミン
Ｄ、２５−ヒドロキシビタミンＤ ３−２６．２３−ラ
クトン及び１α。25-dihydroxyvitamin D, 24.25-dihydroxyvitamin D, 24.24-F2-1α, 25-
Dihydroxyvitamin D, 26,26,26,27,
27.27-Fe-1α, 25-dihydroxyvitamin D, 25-hydroxyvitamin D 3-26.23-Lactone and 1α.
２５−ジヒドロキシビタミンＤ３−２６．２３−ラクト
ンがある。これらのなかでも、１α−ヒドロキシビタミ
ンＤ３，１α、 ２４（Ｒ）−ジヒドロキシビタミンＤ
３，１α、２５−ジヒドロキシビタミンＤ３が好ましく
、特に１α−ヒドロキシビタミンＤ３が好ましい。25-dihydroxyvitamin D3-26.23-lactone. Among these, 1α-hydroxyvitamin D3,1α, 24(R)-dihydroxyvitamin D
3,1α,25-dihydroxyvitamin D3 is preferred, and 1α-hydroxyvitamin D3 is particularly preferred.
これらの有効成分は公知の方法で適当な賦形剤等を用い
て軟カプセル剤、硬カプセル剤２錠剤。These active ingredients are prepared by a known method using appropriate excipients, etc. into soft capsules and two hard capsules.
散剤、顆粒剤、シロップ等の経口剤、注射剤等にして使
用できる。有効成分の投与量は通常０．０１〜１０μｇ
／日／人程度であり、投与回数は通常１〜３回／日で必
り、このような条件を満足するように製剤を調製するの
が好ましい。It can be used in the form of oral preparations such as powders, granules, and syrups, as well as injections. The dose of active ingredient is usually 0.01-10 μg
/day/person, and the number of administrations is usually 1 to 3 times/day, and it is preferable to prepare a preparation to satisfy these conditions.
本発明の治療剤は既存の薬物療法治療剤と併用すること
も可能である。The therapeutic agent of the present invention can also be used in combination with existing pharmacotherapeutic agents.
以下実施例を用いて本発明を詳述する。The present invention will be explained in detail below using Examples.
実施例
吸収不良症候群の病態モデルとして、小腸切除手術を施
したラットを用いて実験を行った。EXAMPLE As a pathological model of malabsorption syndrome, an experiment was conducted using rats that had undergone small intestine resection surgery.
すなわち、６週令Ｃｒｊ：ＷｉＳｔａｒ系雄ラットの空
回腸を回腸末端部１ｃｍから上方に向って７５％切除し
、腸管を端々吻合した。術後１週間正常飼育し、１α−
（ＯＨ）Ｄ３ないし溶媒を強制経口投与した。投与量は
０．０２．０．１０および０．２０μ（Ｉｆ／Ｋｇの３
用量とし、麻酔下、開腹し縫合した偽手術群（ｓｈａｍ
） 、腸切除対照群（ＲｅＳｅＣｔｉＯｒｌ Ｃ０１１
ｔｌ’ＯＩ）には溶媒である０、２％トライトンＸ溶液
を投与した。That is, 75% of the jejuno-ileum of a 6-week-old Crj:WiStar male rat was resected upward from 1 cm of the distal ileum, and the intestinal tract was anastomosed end-to-end. One week after surgery, the 1α-
(OH)D3 or vehicle was orally administered by gavage. The dosage is 0.02, 0.10 and 0.20μ (If/Kg of 3
A sham surgery group (sham surgery) in which the abdomen was opened and sutured under anesthesia.
), intestinal resection control group (ReSeCtiOrl C011
tl'OI), a 0.2% Triton X solution as a solvent was administered.
投与開始後３，６および９週目の糞便中の脂肪をエーテ
ルで抽出しその量を測定した。統計学的解析は、各測定
値の平均値及び標準偏差を求め、腸切除対照群と各投与
群との平均値の差の有意差の検定を両側を一検定を用い
て行った。第１表に結果を示す。Fat in feces at 3, 6 and 9 weeks after the start of administration was extracted with ether and the amount thereof was measured. For statistical analysis, the mean value and standard deviation of each measured value were determined, and the significance of the difference in the mean value between the intestinal resection control group and each administration group was tested using a two-sided one test. Table 1 shows the results.
第１表から明らかなように、１α（ＯＨ）Ｄ３は、０．
０２μｇ／Ｋｇ〜０．２０μｇ／Ｋｑの投与量で腸管切
除後の脂肪便を著明に抑制し、糞便の脂肪含有量を正常
レベルまで改善した。As is clear from Table 1, 1α(OH)D3 is 0.
At doses of 0.02 μg/Kg to 0.20 μg/Kq, steatorrhea after intestinal resection was significantly suppressed and the fat content of feces was improved to normal levels.
Claims (2)
。(1) A therapeutic agent for steatorrhea containing active vitamin D as an active ingredient.
，１α，２４−ジヒドロキシビタミンＤ，１α，２５−
ジヒドロキシビタミンＤ，２４，２５−ジヒドロキシビ
タミンＤ，１α，２４，２５−トリヒドロキシビタミン
Ｄ，２４，２４−Ｆ＿２−１α，２５−ジヒドロキシビ
タミンＤ及び２６，２６，２６，２７，２７，２７−Ｆ
＿６−１α，２５−ジヒドロキシビタミンＤからなる群
から選ばれたものである請求項１記載の脂肪便治療剤。(2) Active vitamin D is 1α-hydroxyvitamin D
,1α,24-dihydroxyvitamin D,1α,25-
Dihydroxyvitamin D, 24,25-dihydroxyvitamin D, 1α,24,25-trihydroxyvitamin D, 24,24-F_2-1α,25-dihydroxyvitamin D and 26,26,26,27,27,27-F
The therapeutic agent for steatorrhea according to claim 1, which is selected from the group consisting of _6-1α,25-dihydroxyvitamin D.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP31645488A JPH02164827A (en) | 1988-12-16 | 1988-12-16 | Remedy for steatorrhea |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP31645488A JPH02164827A (en) | 1988-12-16 | 1988-12-16 | Remedy for steatorrhea |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPH02164827A true JPH02164827A (en) | 1990-06-25 |
Family
ID=18077271
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP31645488A Pending JPH02164827A (en) | 1988-12-16 | 1988-12-16 | Remedy for steatorrhea |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPH02164827A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009115398A1 (en) * | 2008-03-18 | 2009-09-24 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Vitamin d compounds for the treatment of biliary diseases |
-
1988
- 1988-12-16 JP JP31645488A patent/JPH02164827A/en active Pending
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009115398A1 (en) * | 2008-03-18 | 2009-09-24 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Vitamin d compounds for the treatment of biliary diseases |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Cann et al. | What is the benefit of coarse wheat bran in patients with irritable bowel syndrome? | |
| Compston et al. | Plasma levels and intestinal absorption of 25-hydroxyvitamin D in patients with small bowel resection. | |
| US4590184A (en) | Antiosteoporotic pharmaceutical composition containing 24,25-dihydroxycholecalciferol as an active ingredient | |
| Jacobsen et al. | Effect of enterocoated cholestyramine on bowel habit after ileal resection: a double blind crossover study. | |
| US5310560A (en) | Medicine for the treatment of illnesses of the respiratory organs | |
| Kelly et al. | Effect of meal composition on calcium absorption: enhancing effect of carbohydrate polymers | |
| EP0190851B1 (en) | Improved antiinflammatory composition | |
| JPH02164827A (en) | Remedy for steatorrhea | |
| JP2007523162A (en) | Use of 2-methylene-19-nor-20 (S) -1α, 25-dihydroxyvitamin D3 for prevention of bone disease | |
| JPH069405A (en) | Pharmaceutical composition containing 1alpha, 25-dihydroxy-22(e)-dehydro-cholecalciferol | |
| Jonderko et al. | Effect of nifedipine on interdigestive gallbladder volume and postprandial gallbladder emptying in man | |
| Menardi et al. | Biovailability of oral antibiotics in children with short-bowel syndrome | |
| CZ157996A3 (en) | The use of dimeticon for treating constipation | |
| US7288268B2 (en) | Formulation for the treatment of obesity | |
| O'Brien et al. | Idiopathic hypercalcemia of infancy | |
| JP2616845B2 (en) | Blood cholesterol lowering agent containing cysteinolic acid or a bile acid conjugate thereof | |
| Truelove et al. | Treatment of chronic gastric ulcer with gefarnate: a long-term controlled therapeutic trial | |
| Gertner et al. | 1α‐HYDROXYVITAMIN D3 IN THE TREATMENT OF NUTRITIONAL AND METABOLIC RICKETS AND OSTEOMALACIA | |
| US10105375B2 (en) | Combination of low dose 2-methylene-19-nor-(20S)1α, 25-dihydroxyvitamin D3 and calcimimetics to treat secondary hyperparathyroidism | |
| JPH0443887B2 (en) | ||
| JPH08208464A (en) | Agent for treatment and prevention of hyperlipemia | |
| TWI228992B (en) | Treatment of subnormal bone mineral density | |
| EP0295827A2 (en) | Use of 24,25-dihydroxy-cholecalciferol in mending bone fractures | |
| Dyussenova et al. | The Role of Vitamin D in Respiratory Viral Infections and Other Infectious Diseases | |
| Cohen | Peripheral gangrene in a case of myocardial infarction |